IMMUNESENSOR THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.immunesensor.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
- Conditions
- Solid Tumor, Adult
- Interventions
- Drug: Immune Checkpoint Inhibitor
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- ImmuneSensor Therapeutics Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT06026254
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC
- Conditions
- Oligometastatic Disease
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- ImmuneSensor Therapeutics Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05846646
- Locations
- 🇺🇸
City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸The University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies
- Conditions
- Oligoprogressive
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- ImmuneSensor Therapeutics Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05846659
- Locations
- 🇺🇸
City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA, Los Angeles, California, United States
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- ImmuneSensor Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04020185
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States